Empowering SuperCells™. Restoring Hope.
Cell Therapy Meets Unprecedented Scalability
GC Therapeutics (GCTx) is harnessing the world’s first “plug-and-play” induced pluripotent stem cell (iPSC) cellular programming platform, TFome™ (Transcription-Factor-ome, pronounced as tee-eff-ome), to overcome the development and scaling complexities associated with cell therapy and improve patient access across a broad range of therapeutic areas.
“The TFome™ can produce cells better than nature and reduce healthcare burden to improve access to advanced cell therapies.”
-George Church, Ph.D.
Co-Founder & Scientific Advisor
TFome™ (Transcription-Factor-ome) leverages the latest advancements in synthetic biology, gene editing, cell engineering and machine learning, and is designed to revolutionize cell therapy by delivering off-the-shelf iPSC-based medicines at a pace up to 100 times more rapidly than conventional methods via a single-step process with improved potency, efficiency, quality and cost.
We are advancing a pipeline of potential best-in-class cell therapy programs focused on gastrointestinal, neurological and immunological diseases to make a significant impact for patients.
“We’ve assembled a top-tier team of visionary scientists and operators, all of whom are deeply passionate about the unprecedented potential of our science and platform. Their dedication to pushing boundaries and delivering this breakthrough to patients is at the heart of everything we do.”
-Parastoo Khoshakhlagh, Ph.D.
Chief Executive Officer & Co-Founder
Join Us
Join our exceptional team to scale and unleash the next generation of cell therapy-based medicines.